高级检索
徐婧雯, 蒋惠慈, 陈汐敏, 丁贵鹏. 抗体药物治疗黑色素瘤的现状及进展[J]. 中国药科大学学报, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302
引用本文: 徐婧雯, 蒋惠慈, 陈汐敏, 丁贵鹏. 抗体药物治疗黑色素瘤的现状及进展[J]. 中国药科大学学报, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302
shu
XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302
Citation: XU Jingwen, JIANG Huici, CHEN Ximin, DING Guipeng. Advances in antibody drugs for treatment of melanoma[J]. Journal of China Pharmaceutical University, 2014, 45(3): 259-266. DOI: 10.11665/j.issn.1000-5048.20140302
shu

抗体药物治疗黑色素瘤的现状及进展

Advances in antibody drugs for treatment of melanoma

    摘要
  • 摘要: 黑色素瘤的抗体药物治疗方兴未艾，其中抗CTLA-4抗体(ipilimumab和tremelimumab)及抗PD-1抗体(nivolumab 和lambrolizumab)均已完成或正在进行治疗黑色素瘤的Ⅲ期临床试验，针对其他靶点的多个抗体也处于临床试验或临床前研究阶段。本文就抗体药物治疗黑色素瘤的现状及进展做一综述，为黑色素瘤的新药开发和临床治疗提供参考。

     

    Abstract: Antibody drugs play an important role in the treatment of melanoma. Some antibodies such as anti CTLA-4 antibodies(ipilimumab and tremelimumab)and anti PD-1 antibodies(nivolumab and lambrolizumab)have been evaluated under phase III clinical trials. This review briefly discusses recent development and advances of antibody drugs against melanoma.

     

    • HTML全文
    • 参考文献(21)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

访问量：